Table 2.

Metabolic and Hormonal Data of Five Adult Women With DLK1 Defects

Reference ValuesPatient 1APatient 1BPatient 3APatient 3BPatient 4Ea
Glucose, mg/dL (nmol/L)70–99 (3.9–5.5)173 (9.6)112 (6.2)85 (4.7)103 (5.7)124 (6.9)
HbA1c, %4.1–6.09.56.55.98.4
Insulin, μU/mL2.6–24.951.613.621.1
Total cholesterol, mg/dL (mmol/L)<190 (<4.9)192 (5.0)177 (4.6)162 (4.2)206 (5.3)234 (6.1)
Triglycerides, mg/dL (mmol/L)<150 (<1.7)638 (7.2)130 (1.5)62 (0.7)77 (0.9)93 (1.0)
LDL, mg/dL (mmol/L)<130 (<3.4)111 (2.9)86 (2.2)106 (2.7)170 (4.4)
HDL, mg/dL (mmol/L)>40 (>1.0)31 (0.8)41 (1.1)64 (1.7)83 (2.2)43 (1.1)
FSH, IU/L3.5–12.5
25.8–134.8c5.97.17.765.551.5
LH, IU/L2.4–12.63.939.38.128.722.5
Testosterone, ng/dL (nmol/L)20–49 y: ≤48 (1.7) 
>50 y: ≤41 (1.4)32 (1.1)b101 (3.5)24 (0.8)46 (1.6)
Androstenedione, ng/mL (nmol/L)<2.2 (7.7)3.4 (11.9)0.75 (2.6)
Reference ValuesPatient 1APatient 1BPatient 3APatient 3BPatient 4Ea
Glucose, mg/dL (nmol/L)70–99 (3.9–5.5)173 (9.6)112 (6.2)85 (4.7)103 (5.7)124 (6.9)
HbA1c, %4.1–6.09.56.55.98.4
Insulin, μU/mL2.6–24.951.613.621.1
Total cholesterol, mg/dL (mmol/L)<190 (<4.9)192 (5.0)177 (4.6)162 (4.2)206 (5.3)234 (6.1)
Triglycerides, mg/dL (mmol/L)<150 (<1.7)638 (7.2)130 (1.5)62 (0.7)77 (0.9)93 (1.0)
LDL, mg/dL (mmol/L)<130 (<3.4)111 (2.9)86 (2.2)106 (2.7)170 (4.4)
HDL, mg/dL (mmol/L)>40 (>1.0)31 (0.8)41 (1.1)64 (1.7)83 (2.2)43 (1.1)
FSH, IU/L3.5–12.5
25.8–134.8c5.97.17.765.551.5
LH, IU/L2.4–12.63.939.38.128.722.5
Testosterone, ng/dL (nmol/L)20–49 y: ≤48 (1.7) 
>50 y: ≤41 (1.4)32 (1.1)b101 (3.5)24 (0.8)46 (1.6)
Androstenedione, ng/mL (nmol/L)<2.2 (7.7)3.4 (11.9)0.75 (2.6)

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.

a

Clinical data of patients 4A, 4B, 4C, and 4D were previously reported Dauber et al. (18).

b

medroxyprogesterone.

c

Postmenopause levels.

Table 2.

Metabolic and Hormonal Data of Five Adult Women With DLK1 Defects

Reference ValuesPatient 1APatient 1BPatient 3APatient 3BPatient 4Ea
Glucose, mg/dL (nmol/L)70–99 (3.9–5.5)173 (9.6)112 (6.2)85 (4.7)103 (5.7)124 (6.9)
HbA1c, %4.1–6.09.56.55.98.4
Insulin, μU/mL2.6–24.951.613.621.1
Total cholesterol, mg/dL (mmol/L)<190 (<4.9)192 (5.0)177 (4.6)162 (4.2)206 (5.3)234 (6.1)
Triglycerides, mg/dL (mmol/L)<150 (<1.7)638 (7.2)130 (1.5)62 (0.7)77 (0.9)93 (1.0)
LDL, mg/dL (mmol/L)<130 (<3.4)111 (2.9)86 (2.2)106 (2.7)170 (4.4)
HDL, mg/dL (mmol/L)>40 (>1.0)31 (0.8)41 (1.1)64 (1.7)83 (2.2)43 (1.1)
FSH, IU/L3.5–12.5
25.8–134.8c5.97.17.765.551.5
LH, IU/L2.4–12.63.939.38.128.722.5
Testosterone, ng/dL (nmol/L)20–49 y: ≤48 (1.7) 
>50 y: ≤41 (1.4)32 (1.1)b101 (3.5)24 (0.8)46 (1.6)
Androstenedione, ng/mL (nmol/L)<2.2 (7.7)3.4 (11.9)0.75 (2.6)
Reference ValuesPatient 1APatient 1BPatient 3APatient 3BPatient 4Ea
Glucose, mg/dL (nmol/L)70–99 (3.9–5.5)173 (9.6)112 (6.2)85 (4.7)103 (5.7)124 (6.9)
HbA1c, %4.1–6.09.56.55.98.4
Insulin, μU/mL2.6–24.951.613.621.1
Total cholesterol, mg/dL (mmol/L)<190 (<4.9)192 (5.0)177 (4.6)162 (4.2)206 (5.3)234 (6.1)
Triglycerides, mg/dL (mmol/L)<150 (<1.7)638 (7.2)130 (1.5)62 (0.7)77 (0.9)93 (1.0)
LDL, mg/dL (mmol/L)<130 (<3.4)111 (2.9)86 (2.2)106 (2.7)170 (4.4)
HDL, mg/dL (mmol/L)>40 (>1.0)31 (0.8)41 (1.1)64 (1.7)83 (2.2)43 (1.1)
FSH, IU/L3.5–12.5
25.8–134.8c5.97.17.765.551.5
LH, IU/L2.4–12.63.939.38.128.722.5
Testosterone, ng/dL (nmol/L)20–49 y: ≤48 (1.7) 
>50 y: ≤41 (1.4)32 (1.1)b101 (3.5)24 (0.8)46 (1.6)
Androstenedione, ng/mL (nmol/L)<2.2 (7.7)3.4 (11.9)0.75 (2.6)

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.

a

Clinical data of patients 4A, 4B, 4C, and 4D were previously reported Dauber et al. (18).

b

medroxyprogesterone.

c

Postmenopause levels.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close